Skip to main content
Veterinary Medicines

Proteq West Nile (--) - Suspension for injection

Authorised
  • Canarypox virus, strain vCP2017, expressing preM and E proteins genes of West Nile virus, Live

Product identification

Medicine name:
Proteq West Nile (--) - Suspension for injection
Active substance:
  • Canarypox virus, strain vCP2017, expressing preM and E proteins genes of West Nile virus, Live
Target species:
  • Horse
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Canarypox virus, strain vCP2017, expressing preM and E proteins genes of West Nile virus, Live
    Presentation_strength:6.0 ≤ R ≤ 7.8 log 10 CCID50 Reference:Hse Comments:Supply of antigen Index:0
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Horse
      • Not applicable
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI05AX
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Package description:
  • Packaging:Vial (glass), Package_size:10 vials, Content:1 ml (1 dose)
  • Packaging:Vial (glass), Package_size:5 vials, Content:1 ml (1 dose)
  • Packaging:Vial (glass), Package_size:2 vials, Content:1 ml (1 dose)
  • Packaging:Vial (glass), Package_size:1 vial, Content:1 ml (1 dose)

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

English (PDF)
Published on: 11/07/2023
Download
Bulgarian (PDF)
Published on: 11/07/2023
Croatian (PDF)
Published on: 11/07/2023
Czech (PDF)
Published on: 11/07/2023
Danish (PDF)
Published on: 11/07/2023
Dutch (PDF)
Published on: 11/07/2023
Estonian (PDF)
Published on: 11/07/2023
Finnish (PDF)
Published on: 11/07/2023
French (PDF)
Published on: 11/07/2023
German (PDF)
Published on: 11/07/2023
Greek (PDF)
Published on: 11/07/2023
Hungarian (PDF)
Published on: 11/07/2023
Icelandic (PDF)
Published on: 11/07/2023
Italian (PDF)
Published on: 11/07/2023
Latvian (PDF)
Published on: 11/07/2023
Lithuanian (PDF)
Published on: 11/07/2023
Maltese (PDF)
Published on: 11/07/2023
Norwegian (PDF)
Published on: 11/07/2023
Polish (PDF)
Published on: 11/07/2023
Portuguese (PDF)
Published on: 11/07/2023
Romanian (PDF)
Published on: 11/07/2023
Slovak (PDF)
Published on: 11/07/2023
Slovenian (PDF)
Published on: 11/07/2023
Spanish (PDF)
Published on: 11/07/2023
Swedish (PDF)
Published on: 11/07/2023

ema-puar-proteq-west-nile-v-2005-par-en.pdf

English (PDF)
Published on: 15/03/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."